• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

    6/2/25 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZEAL alert in real time by email

    Press release – No. 10 / 2025

    Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

    Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) ("Zealand") (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS).  

    The submission of the MAA to the EMA for glepaglutide administered twice weekly for the treatment of SBS is based on results from a pivotal Phase 3 trial (EASE-1), supported by interim results from two ongoing long-term extension trials (EASE-2 and EASE-3) and results from a mechanistic trial (EASE-4).

    "We are pleased to bring our potential best-in-class GLP-2 analog, glepaglutide, one step closer to patients in Europe living with short bowel syndrome with intestinal failure, who urgently need more effective and more convenient treatment options," said David Kendall, MD, Chief Medical Officer of Zealand Pharma. "We believe that glepaglutide, administered twice weekly, offers meaningful potential to reduce both the burden of parenteral support and the inconvenience of daily dosing required with the only currently available GLP-2 therapy. Looking ahead, we expect to initiate the EASE-5 Phase 3 trial in the second half of the year to obtain further confirmatory safety and efficacy data on the twice weekly dosing regimen, supporting regulatory submission in the U.S."

    About glepaglutide

    Glepaglutide is a long-acting GLP-2 analog in development as a potential treatment option for short bowel syndrome (SBS). Glepaglutide is developed as a liquid product in an autoinjector designed for subcutaneous administration by twice weekly dosing, aimed to reduce, or eliminate, the need for parenteral support in people living with SBS. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for glepaglutide for the treatment of SBS.

    About the EASE Clinical Trial Program

    The Phase 3 program, named EASE, is designed to evaluate the potential for glepaglutide to reduce or eliminate the need for parenteral support in SBS patients with intestinal failure.

    EASE-1 (NCT03690206) was a randomized, double-blind Phase 3 trial that enrolled a total of 106 SBS patients with intestinal failure who were dependent on parenteral support for at least three days per week. Patients were evenly randomized to receive treatment with 10 mg glepaglutide administered either once or twice weekly, or placebo. The primary endpoint in the trial was the absolute change in weekly parenteral support volume from baseline at 24 weeks. At 24 weeks, glepaglutide administered twice weekly significantly reduced the total weekly volume of PS by 5.13 liters/week, compared to a reduction of 2.85 liters/week in the placebo group (p=0.0039). When administered once weekly, glepaglutide treatment resulted in a reduction in weekly PS of 3.13 liters/week, however this did not achieve statistical significance. A total of 9 patients treated with glepaglutide were completely weaned off PS (achieving enteral autonomy), while no placebo-treated patients were able to discontinue PS. For patients treated with glepaglutide twice weekly, 14% of patients (n=5) achieved enteral autonomy.

    In total, 102 of 106 participating patients completed EASE-1, of which 96 continued into the ongoing two-year, long-term safety and efficacy extension trial, EASE-2.

    EASE-2 (NCT03905707) is a randomized, double-blind trial in which SBS patients continued their randomly assigned treatment from EASE-1 with glepaglutide 10 mg once- or twice-weekly. Patients who received placebo in EASE-1 were re-randomized to treatment with either glepaglutide 10 mg once- or twice-weekly. In an interim analysis conducted after at least six months of treatment, clinical response to glepaglutide across the key efficacy endpoints was generally maintained or showed continued improvement, including additional patients on both doses weaning off PS.

    Patients who complete EASE-2 are eligible to participate in EASE-3 (NCT04881825), evaluating glepaglutide administered once weekly using an autoinjector. An interim analysis of EASE-3, conducted with the first 57 patients rolled over from EASE 2, showed that the reduction in prescribed PS was generally maintained.

    EASE-4 (NCT04991311) was a Phase 3b trial to assess mechanistic effects of glepaglutide on intestinal fluid and energy uptake. The trial provides evidence of the pharmacodynamic effects of glepaglutide in improving intestinal absorption.

    In the second half of 2025, Zealand Pharma expects to initiate EASE-5, a single Phase 3 clinical trial that is anticipated to provide further confirmatory evidence for a regulatory submission in the U.S.

    About Zealand Pharma A/S

    Zealand Pharma A/S (NASDAQ:ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

    Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit www.zealandpharma.com.

    Forward looking statements

    This press release contains "forward-looking statements", as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company's pre-clinical and clinical trials and the reporting of data therefrom. These forward-looking statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to affect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this company announcement and are based on information available to Zealand Pharma as of the date of this announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

    Contacts

    Adam Lange (Investors)

    Vice President, Investor Relations

    [email protected]

    Neshat Ahmadi (Investors)

    Investor Relations Manager

    [email protected]

    Anna Krassowska, PhD (Investors and Media)

    Vice President, Investor Relations & Corporate Communications

    [email protected]



    Primary Logo

    Get the next $ZEAL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ZEAL

    DatePrice TargetRatingAnalyst
    3/5/2024Buy
    Berenberg
    8/8/2023Equal-Weight
    Morgan Stanley
    11/16/2022Overweight → Equal-Weight
    Morgan Stanley
    1/11/2022Hold → Buy
    Jefferies
    More analyst ratings

    $ZEAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Berenberg initiated coverage on Zealand Pharma

      Berenberg initiated coverage of Zealand Pharma with a rating of Buy

      3/5/24 7:30:01 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley resumed coverage on Zealand Pharma

      Morgan Stanley resumed coverage of Zealand Pharma with a rating of Equal-Weight

      8/8/23 7:40:54 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma downgraded by Morgan Stanley

      Morgan Stanley downgraded Zealand Pharma from Overweight to Equal-Weight

      11/16/22 9:37:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZEAL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

      Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 18 July 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 17 July 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,135,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 10.001% of the total share capital and 10.001% o

      7/18/25 12:30:00 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

      Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred. In Company Announcement No. 14 / 2025 dated June 6, 2025, Zealand Pharma announced a share capital increase due to the ex

      6/30/25 11:05:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

      Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modificationsTreatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapiesUnique, dual mechanism, including GLP-2 activity, designed to target obesity-related comorbid conditions driven by low-grade inflammation Copenha

      6/18/25 11:29:44 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZEAL
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Zealand Pharma A/S

      15F-12B - Zealand Pharma A/S (0001674988) (Filer)

      9/30/22 5:24:36 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Zealand Pharma A/S

      S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

      9/20/22 5:20:13 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Zealand Pharma A/S

      S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

      9/20/22 5:16:47 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZEAL
    Financials

    Live finance-specific insights

    See more
    • Zealand Pharma increases its share capital as a result of the exercise of employee warrants

      Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pha

      6/6/25 4:00:00 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma Announces Financial Results for the First Three Months of 2025

      Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic partnership for petrelintide create strong foundation for accelerated growth. Entered historic and transformative partnership with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management and rapidly expand into related indications, aiming to establish the leading amylin-based franchise.Enrolled the last participant in the large, global Phase 2 ZUPREME-1 trial with petrelintide in people with overweight or obesity, thre

      5/8/25 1:00:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results

      Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 8, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter / first three months of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Ke

      5/1/25 11:05:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZEAL
    Leadership Updates

    Live Leadership Updates

    See more
    • Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

      Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently appointed CSO Utpal Singh to strengthen Zealand Pharma's R&D leadership and progress its differentiated clinical pipeline of potential best-in-class peptide therapeutics Copenhagen, Denmark, May 19, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnolog

      5/19/25 9:00:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

      Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide medicines, investing in new technologies including data and computational science Utpal to expand the global scientific team to drive Zealand Pharma's next wave of highly differentiated, innovative therapies, building on the Company's strong drug development heritage Copenhagen, Denmark, 23 April 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)

      4/23/25 9:00:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

      Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company's board of directors. It is expected that Enrique Conterno and Elaine Sullivan will stand for election to Zealand Pharma's board of directors at the company's 2024 Annual General Meeting. "As board observes, Enrique and Elaine collectively bring decades

      11/30/23 2:00:00 AM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZEAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Zealand Pharma A/S (Amendment)

      SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)

      2/14/22 12:27:01 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)

      2/3/21 1:13:21 PM ET
      $ZEAL
      Biotechnology: Pharmaceutical Preparations
      Health Care